1. Opening Hook
Just when the street thought pharma was done with diabetes drama, Eris decided to remix the script. Innovators exit, generics enter, GLPs knock loudly, and management calmly says, “We planned this.” Q2 FY26 wasn’t about flashy one-liners—it was about quietly loading the gun. Insulins are shifting hands, GLP-1s are being hyped like IPL auctions, and Europe suddenly wants Eris-made injectables.
Margins expanded, debt shrank, capex accelerated—and yet, nothing “extraordinary,” if you ask management. Apparently, ₹700–800 crore CDMO order books just happen on Tuesdays.
Stick around. The insulin opportunity peaks in April–June, GLP launches loom, and Europe might finally pay premium prices. Things get spicy after the footnotes.
2. At a Glance
- Revenue up 10% (DBF): Beating the market by 30%, while blaming regulators for the rest.
- EBITDA margin 37.5%: When scale works, even pharma smiles.
- PAT up 39% YoY: EPS acceleration finally clocked in on time.
- Biocon EBITDA margin at 32%: From ugly duckling to profit swan.
- Net debt ₹2,278 cr: Still heavy, but slimming faster than expected.
3. Management’s Key Commentary
“We delivered 10% domestic formulations growth, 30% ahead of the market.”
(Market jogged, Eris took an Uber.) 😏
“The delay in gSaxenda approval impacted growth.”
(Regulators ruined our perfect PowerPoint.)
“RHI cartridge monetisation starts December.”
(Winter is coming—for competitors.)
“Biocon margins improved from 19% at acquisition to 32% now.”
(Turns out integration isn’t a buzzword.)
“We see ₹125–150 crore CDMO revenue next year from Europe.”
(Finally, Europe pays instead of inspects.)
“GLP is a billion-dollar opportunity in year one.”
(Everyone laughed last year. Not anymore.) 😎
“Debt-to-EBITDA will fall
